Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 4/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | XIAP | P98170 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17062865 | 1.00 | CMA1 (0.41) | CMA1TRPA1HDAC8XIAPELANE | |
| SCHEMBL19181285 | 0.91 | ACE (0.43) | ACESCN9A | |
| SCHEMBL19181283 | 0.91 | ACE (0.43) | ACESCN9A | |
| SCHEMBL19181306 | 0.91 | ACE (0.43) | ACESCN9A | |
| SCHEMBL16466125 | 0.85 | XIAP (0.39) | XIAPELANEACE | |
| SCHEMBL17062296 | 0.85 | XIAP (0.39) | XIAPELANEACE | |
| SCHEMBL16466124 | 0.85 | XIAP (0.39) | XIAPELANEACE | |
| SCHEMBL17094803 | 0.85 | XIAP (0.39) | XIAPELANEACE | |
| SCHEMBL16466122 | 0.85 | XIAP (0.42) | XIAPELANEACE | |
| SCHEMBL17094824 | 0.85 | XIAP (0.42) | XIAPELANEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2906560-B1 | AZAINDOLINES HAVING ACTIVITY AS INHIBITORS OF IAP | HOFFMANN LA ROCHE (CH) | 2017-02-22 | — | — | EP | disclosed |
| EP-2906559-B1 | AZAINDOLINES | HOFFMANN LA ROCHE (CH) | 2017-02-08 | — | — | EP | disclosed |
| US-9340573-B2 | Azaindolines | HOFFMANN-LA ROCHE INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9309248-B2 | Azaindolines | HOFFMANN-LA ROCHE INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20150266879-A1 | AZAINDOLINES | HOFFMANN-LA ROCHE INC. | 2015-09-24 | — | — | US | disclosed |
| US-20150252072-A1 | AZAINDOLINES | HOFFMANN-LA ROCHE INC. | 2015-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266879-A1 | AZAINDOLINES | AZI2, H1-5, CCNY | CMA1 2634/4885TRPA1 4507/4885HDAC8 146/4885 |
| US-20150252072-A1 | AZAINDOLINES | AZI2, H1-5, H1-3 | CMA1 2465/4885TRPA1 4555/4885HDAC8 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.